Overview and audit against Motor Neurone Disease (MND) Association guidelines of a MND consultant’s practice over the last 3 years at the [Hospital]

  • Dominic Adam Worku University of Birmingham
  • Unnat Krishna University of Birmingham
  • Karen E Morrison University of Southampton
Keywords: Neurology, Motor Neurone Disease, Audit

Abstract


Background: Motor neurone disease (MND) is an incurable neurodegenerative condition. Recent guidelines from the MND Association UK (MNDA) emphasise prompt diagnosis and monitoring of quality of life (QOL). However, primary literature indicates that diagnosis is often delayed through several factors, including unawareness of how MND presents and delays through multiple secondary referrals. The [hospital] operates an internationally-recognised MND clinic whose service has not been audited against the MNDA UK guidelines for the last 3 years.

Aim: To assess how well the MND consultant’s service ensures prompt diagnosis and the provision of end-of-life care or appropriate respiratory or nutritional support.

Methods: Using the [hospital’s] database, records from 77 patients consulted consecutively in the MND clinic were obtained. Service parameters were compared against reference standards for diagnostic delay and treatment provision.

Results:  84.4% of referrals came from neurologists outside of the MND service, with only 13% from general practitioners. On average, it took 14.7 months for patients to be seen in the MND clinic following symptom onset. Riluzole and percutaneous endoscopic gastrostomy (PEG) were prescribed faster in bulbar-onset versus limb-onset patients, by 4 times and 9 times respectively. End-of-life care discussion was recorded for 26% of patients.

Conclusion:    Diagnosing MND remains challenging for primary care physicians, which may be alleviated by disseminating recent Red Flag Committee guidelines. Investigation and treatment provision differed between MND subtypes, given the poorer prognosis associated with bulbar-onset. End-of-life care documentation remains low, which is an issue for the multi-disciplinary team (MDT) to resolve through incorporating palliative services. 

References

1. Tidy C. Motor Neurone Disease. Patient UK Professional Reference [Online] 2015 [Cited 2016 Apr 7]. Available from URL:http://patient.info/doctor/motor-neurone-disease-pro

2. McDermott CJ. Diagnosis and management of motor neurone disease. BMJ [online] 2008 [Cited 2016 Apr 7]. Available from URL: http://www.bmj.com/content/336/7645/658


3. Chio A., Logroscino G., Traynor BJ., Collins J., Simeone JC., Goldstein LA., et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology [online] 2013 [Cited 2016 Apr 7]; 41(2): p118-130. Available from URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049265/

4. Motor Neurone Disease Association Outcome Standards. MNDA [online] 2015. Available from URL: http://www.mndassociation.org/wp-content/uploads/Outcomes-Standards.pdf?c8bf39


5. Andersen PM., Abraham PM., Abrahams S., Borasio GD., de Carvalho M., Chio A., et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)—revised report of an EFNS task force. Eur J Neurol [online] 2012 [Cited 2016 Apr 7]; 19(3): p360-375. Available from URL: http://www.ncbi.nlm.nih.gov/pubmed/21914052

6. Murray L., Butow PN. Advance care planning in motor neuron disease: A systematic review. Palliat Support Care [online] 2015 [Cited 2016 Apr 7]; 14: p1-22. Available from URL: http://www.ncbi.nlm.nih.gov/pubmed/26462880


7. McKim DA., King J., Walker K., Leblanc C., Timpson D., Wilson KG., et al. Formal ventilation patient education for ALS predicts real-life choices. Amyotroph lateral scler [online] 2012 [Cited 2016 Apr 7]; 13(1): p59-65. Available from URL: http://www.ncbi.nlm.nih.gov/pubmed/22214354

8. Loan JJM., Connolly SD., Haunschmidt DZ., Bell SB., Clarke SA., Kelly J., et al. Treatment options in motor neuron disease: Amyotrophic lateral sclerosis and spinal muscular atrophy. Journal of Young Investigators [online] 2012; 24(4): p33-54. Available from URL: http://www.jyi.org/wp-content/uploads/Comparing-Treatment-Options-in-Motor-Neurone-Disease-Amyotrophic-Lateral-Sclerosis-and-Spinal-Muscular-Atrophy.pdf



9. Davies L., Pizzaro-Duhart R., Rafi I., Bedford J., Fairfield H. Morrison K. Painless, progressive weakness – Could this be Motor Neurone Disease? MNDA, RCGP [online] 2014 [Cited 2016 Apr 7]. Available from URL: http://www.mndassociation.org/wp-content/uploads/2015/02/Red-flags-FINAL-2.pdf?c8bf39



10. “Malnutrition Universal Screening Tool.” Bapen [online]. Available from URL: http://www.bapen.org.uk/pdfs/must/must_full.pdf

11. Inquiry into access to specialist palliative care for people with MND: Summary of recommendations. All-party parliamentary group on motor neurone disease. Available from URL: http://www.mndassociation.org/wp-content/uploads/2015/02/APPG%20inquiry%20-%20summary%20report.doc_1853.pdf
Published
31-Dec-2017
How to Cite
Worku, D., Krishna, U., & Morrison, K. (2017, December 31). Overview and audit against Motor Neurone Disease (MND) Association guidelines of a MND consultant’s practice over the last 3 years at the [Hospital]. Res Medica, 24(1), 65-74. https://doi.org/https://doi.org/10.2218/resmedica.v24i1.1563